is since dec. 2010
Company Overview
Talon Therapeutics, Inc. is a San Francisco Bay Area-based biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
Talon Therapeutics, Inc.
2207 Bridgepointe Parkway
Suite 250
San Mateo, CA 94404
United States - http://maps.yahoo.com/maps_result?addr=2207%20Bridgepointe%20Parkway%20Suite%20250&csz=San%20Mateo%20CA%2094404&country=United%20States" rel="nofollow">Map
Phone: 650-588-6404
Fax: 650-588-2787
Website: http://www.talontx.com
Talon Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. Its lead product candidate, Marqibo (vincristine sulfate liposomes injection), is a targeted Optisome encapsulated formulation product candidate, which is in the development for the treatment of adult acute lymphoblastic leukemia. The company's product candidates also include Menadione Topical Lotion, a supportive care product candidate that completed Phase 1 clinical trial for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, a type of anti-cancer agent used in the treatment of lung, colon, head and neck, pancreatic, and breast cancer; and Brakiva (topotecan liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of metastatic carcinoma of the ovary and small cell lung cancer. In addition, its development stage product consists of Alocrest (vinorelbine liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, such as non-small-cell lung cancer. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. The company was formerly known as Hana Biosciences, Inc. and changed its name to Talon Therapeutics, Inc. in December 2010. Talon Therapeutics, Inc. was founded in 2002 and is based in San Mateo, California
Current Pipeline
Marqibo® (vincristine sulfate liposomes injection, OPTISOME™)
A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin's lymphoma (NHL) and ALL. Hana has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma. More Details »
Alocrest™ (vinorelbine liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity. More Details »
Brakiva™ (topotecan liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan. More Details »
Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor. More Details »
Presentations
and more:
http://ir.talontx.com/presentations.cfm
INFOS
-
OTC Market Tier
Pink Quote/OTCBB -
Primary SIC - Industry Classification
2834 - Pharmaceutical preparations
-
State Of Incorporation
DE -
Jurisdiction Of Incorporation
United States
Board of Directors
Steven R. Deitcher, M.D.
President & Chief Executive Officer
Nishan de Silva, M.D.
Principal, Warburg Pincus
Andrew K. Ferrer
Associate, Warburg Pincus
Howard P. Furst, M.D.
Partner, Deerfield Management
Jonathan S. Leff
Managing Director, Warburg Pincus
Paul V. Maier
Chief Financial Officer, Sequenom, Inc.
Leon E. Rosenberg, M.D. (Chairman)
Professor of Molecular Biology, Princeton University
Robert J. Spiegel, M.D.
Director
-
SEC Reporting Status
SEC Reporting Company -
CIK
0001140028 -
Fiscal Year End
12/31
Current Share Structure
Current as of 12/31/2010
A/S 350,000,000
O/S 21,242,772 (Mar 28, 2011)
FLOAT 16.48M
Transfer Agent
Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, CO 80209
Recent news
Charting
New presentation from tlon from 3-30-12
http://files.shareholder.com/downloads/HNAB/1722627662x0x556820/A59F1E05-C4F6-4235-B039-7B3CCE775B48/talontx_corp_pres.pdf
